Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SLDB Solid Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: SLDB
Price (delayed)
$6.47
Market cap
$501.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.01
Enterprise value
$314.52M
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by
Highlights
The equity has surged by 115% since the previous quarter and by 40% year-on-year
The EPS rose by 24% year-on-year
SLDB's quick ratio has surged by 117% since the previous quarter but it is down by 26% year-on-year
The net income has shrunk by 55% YoY and by 12% QoQ
Key stats
What are the main financial stats of SLDB
Market
Valuations
Earnings
Shares outstanding
77.52M
Market cap
$501.52M
Enterprise value
$314.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$142.92M
Net income
-$139.68M
EBIT
-$139.36M
EBITDA
-$133.86M
Free cash flow
-$107.3M
Per share
Balance sheet
Liquidity
EPS
-$3.01
EPS diluted
-$3.01
Free cash flow per share
-$1.62
Book value per share
$3.8
Revenue per share
$0
TBVPS
$5.18
Total assets
$343.9M
Total liabilities
$49.44M
Debt
$23.63M
Equity
$294.46M
Working capital
$284.63M
Debt to equity
0.08
Current ratio
10.89
Quick ratio
10.66
Net debt/EBITDA
1.4
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.3%
Return on equity
-70.5%
Return on invested capital
-106.1%
Return on capital employed
-44.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLDB stock price
How has the Solid Biosciences stock price performed over time
Intraday
11.74%
1 week
23%
1 month
39.14%
1 year
-17.05%
YTD
61.75%
QTD
32.85%
Financial performance
How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.92M
Net income
-$139.68M
Gross margin
N/A
Net margin
N/A
The net income has shrunk by 55% YoY and by 12% QoQ
The operating income has declined by 44% year-on-year and by 10% since the previous quarter
Price vs fundamentals
How does SLDB's price correlate with its fundamentals
Growth
What is Solid Biosciences's growth rate over time
Valuation
What is Solid Biosciences stock price valuation
P/E
N/A
P/B
1.7
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 24% year-on-year
The equity has surged by 115% since the previous quarter and by 40% year-on-year
The price to book (P/B) is 27% more than the last 4 quarters average of 1.2 and 17% more than the 5-year quarterly average of 1.3
Efficiency
How efficient is Solid Biosciences business performance
The ROIC has shrunk by 51% YoY and by 15% QoQ
The return on assets has declined by 27% year-on-year
Solid Biosciences's return on equity has decreased by 26% YoY
Dividends
What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLDB.
Financial health
How did Solid Biosciences financials performed over time
SLDB's quick ratio has surged by 117% since the previous quarter but it is down by 26% year-on-year
Solid Biosciences's current ratio has surged by 109% QoQ but it has decreased by 27% YoY
The debt is 92% lower than the equity
The equity has surged by 115% since the previous quarter and by 40% year-on-year
The debt to equity has plunged by 56% from the previous quarter and by 33% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.